Drugs / TY-9591
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05871905 | Jun → Nov 2023 | — | TYK Medicines, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04798638 | Apr → Sep 2021 | — | TYK Medicines, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04204473 | May 2020 → Mar 2023 | non-small cell lung carcinoma | TYK Medicines, Inc | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06672068 | Feb 2025 → Dec 2027 expected | non-small cell lung carcinoma | TYK Medicines, Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05948813 | Aug 2023 → Jun 2025 overdue | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | TYK Medicines, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT05146219 | Apr 2022 → Mar 2024 | metastatic malignant neoplasm in the brain, neoplastic meningitis, non-small cell lung carcinoma | TYK Medicines, Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05382728 | Jun 2022 → May 2025 overdue | non-small cell lung carcinoma | TYK Medicines, Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TY-9591 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05871905 ↗ |
| Known as | asandeutertinib | “This phase 1 study evaluated the safety, pharmacokinetics, and preliminary efficacy of TY-9591 (asandeutertinib), a deuterated osimertinib derivative.” PMID 39929334 ↗ Feb 2025 |
| Route | Oral | “multiple doses of TY-9591 administered orally once daily” NCT04204473 ↗ |